

Not All Pericytes Are Born Equal: Pericytes from Human Adult Tissues Present Different Differentiation Properties

Bianca Vezzani,* Enrico Pierantozzi,* and Vincenzo Sorrentino

Pericytes (PCs) have been recognized for a long time only as structural cells of the blood vessels. The identification of tight contacts with endothelial cells and the ability to interact with surrounding cells through paracrine signaling revealed additional functions of PCs in maintaining the homeostasis of the perivascular environment. PCs got the front page, in the late 1990s, after the identification and characterization of a new embryonic cell population, the mesoangioblasts, from which PCs present in the adult organism are thought to derive. From these studies, it was clear that PCs were also endowed with multipotent mesodermal abilities. Furthermore, their ability to cross the vascular wall and to reconstitute skeletal muscle tissue after systemic injection opened the way to a number of studies aimed to develop therapeutic protocols for a cell therapy of muscular dystrophy. This has resulted in a major effort to characterize pericytic cell populations from skeletal muscle and other adult tissues. Additional studies also addressed their relationship with other cells of the perivascular compartment and with mesenchymal stem cells. These data have provided initial evidence that PCs from different adult tissues might be endowed with distinctive differentiation abilities. This would suggest that the multipotent mesenchymal ability of PCs might be restrained within different tissues, likely depending on the specific cell renewal and repair requirements of each tissue. This review presents current knowledge on human PCs and highlights recent data on the differentiation properties of PCs isolated from different adult tissues.

A Historical Introduction

PERICYTES (PCs) WERE INITIALLY described by the French scientist Charles-Marie Benjamin Rouget as a population of perivascular contractile cells surrounding the endothelial cells (ECs) of small blood vessels. They were named Rouget cells after their discoverer, but later the term “pericytes,” which refers to their location around small vessels, was introduced [1,2].

PCs, surrounded by the basal membrane, establish intimate contacts, called peg-and-sockets, with ECs. These contacts are composed of cytoplasmic elongations of PCs (pegs), invaginated into the ECs membrane (sockets) [3–5]. Interactions between PCs and ECs take place through tight and gap junctions rich in connexin 43 that are present at the contact sites [6–8] and are stabilized by adhesion plaques between these cells and fibronectin in the extracellular matrix [8–10]. These multiple interactions have the role of reinforcing the communication between PCs and ECs and contribute to the correct distribution of the mechanical contractile force generated by vascular smooth muscle cells (VSMCs) [11–14].

In the past years, different names, such as mural cells, PCs, and VSMCs, have been used interchangeably to refer to all the

perivascular cells that support microvasculature and establish intimate cell-to-cell contacts [15]. However, more recently, differences between PCs and VSMCs have been recognized, indicating that despite sharing common markers, they represent two distinct cell populations that can be distinguished depending on their specific localization and functional role [2,11,15,16]. Indeed, PCs are predominantly localized around small vessels, whereas VSMCs are mainly positioned around larger vessels. In the latter anatomical location, VSMCs are wrapped in multiple layers perpendicularly distributed along the axis of vessels, thus providing structural support in regulating blood flow and in controlling, especially in arterioles, the diameter of the vessels. In contrast, PCs are longitudinally oriented with respect to the axis of vessels and are generally organized in a single cell layer [11,16,17].

Another distinctive feature of PCs and VSMCs is their relative abundance around the vasculature. In fact, the number of VSMCs and PCs may vary depending on of the caliber of the vessel and among different tissues. For instance, in retinal capillaries, VSMCs and PCs are present in a 1:1 ratio, whereas in other tissues VSMCs are usually more represented than PCs [18,19]. Moreover, VSMCs, at variance with PCs, do not establish direct contacts with ECs, as they are separated

Molecular Medicine Section, Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.

*These authors contributed equally to this article.

from the endothelium by the basal membrane or, in case of larger arteries, by the intima layer [11].

Based on this evidence, PCs, although considered for many years the microvascular counterpart of VSMCs, are now recognized as a well-defined perivascular cell population that plays a role in regulating homeostatic processes between the ECs and surrounding tissue [20–22]. This function is of increased significance in tissues, like the central nervous system, where PCs contribute to form a functional barrier with the blood stream [23].

A novel interest in PCs was stimulated by studies that revealed that PCs are capable of differentiating into several mesodermal cell lineages, thus revealing additional and unexpected properties of these cells that have opened a new area of research oriented toward a possible use of PCs in the regenerative medicine field [21,24–26]. These properties of PCs should not surprise, as we are aware now of the contribution provided by a number of stem/progenitor cells, including multipotent or more lineage-restricted cells, associated with blood vessels in maintaining the homeostasis of tissues [27]. Furthermore, the cellular dynamics of blood vessels have attracted increasing interest over the past years since, in addition to their physiological role, they are also involved in pathological conditions such as atherosclerosis and cancer [19,28,29].

Recognition of the ability of PCs to differentiate into different mesodermal lineages has also opened new questions about their relationships with others stem/progenitor cells associated with the vascular compartment and more, in general, with mesenchymal stem cells (MSCs) derived from connective tissue [30].

PCs: From the Developing Embryo to the Perivascular Compartment of Adult Tissues

Studies based on chimeras and cell-fate mapping indicated that VSMCs arise from distinct embryonic compartments. In fact, lineage-tracing experiments of VSMC progenitors in the embryo and in the adult organism revealed that VSMCs might derive from neural crest, proepicardium, mesothelium, the secondary heart field, and somitic and splanchnic mesoderm [17,31,32]. In a similar manner, PCs found in the head and thymus are apparently also derived from the cranial neural crest, whereas PCs residing in other anatomical regions of the adult body are likely derived from the mesoderm [2,16,31].

In 1999, Cossu and collaborators reported the characterization of a novel cell population following *in vitro* culture of E9.5 mouse dorsal aorta explants. These cells coexpressed early endothelial and myogenic markers. After the initial association of mesoangioblasts with the embryonic dorsal aorta, additional experiments based on lineage tracing indicated that these cells can originate from the hemogenic endothelium [33]. In addition, these cells were capable of giving rise to multiple differentiated cells of mesodermal derivatives, after both *in vivo* transplantation and *in vitro* culture [24]. Due to their capacity to originate both vascular and extravascular mesodermal derivatives, this cell population of embryonic aorta-associated multipotent progenitors was named mesoangioblasts [34].

However, much of the interest on mesoangioblasts, and later on adult PCs, was triggered by the initial evidence that

transplant of murine mesoangioblasts contributed to the growth and regeneration of muscle fibers *in vivo* [24]. Additional experiments elegantly demonstrated also the ability of systemically transplanted mesoangioblasts to reach the developing skeletal muscle fibers through the circulation [35].

Notably, the *in vivo* potential of mesoangioblasts was not limited only to skeletal myogenesis. Experiments on chimeric embryos, where embryonic aorta-derived cells from quail or mouse were grafted into chick embryo, revealed that mesoangioblasts initially integrated into the vasculature of the host, actively concurring to the generation of chimeric microvasculature in different tissues. Grafted mesoangioblasts were finally found as a fully differentiated cell component in a broad range of mesodermal tissues [34]. The ability of mesoangioblasts to travel through the bloodstream led to the hypothesis that, during embryonic development, they could migrate from the dorsal aorta along the forming blood vessels, contributing to the perivascular cell compartment of postnatal tissues [36].

On this basis, it is evident that adult PCs have some of the functional properties observed in mesoangioblasts, including the mesenchymal, endothelial, and vasculogenic abilities [21,37].

Stem and Progenitor Cells Associated with the Wall of Blood Vessels

Regardless of their likely relationship with the embryonic mesoangioblasts, PCs present in adult tissues represent a population of cells of the perivascular compartment that can differentiate into different mesodermal cell types [37,38].

A well-studied cell population that shares several properties with adult PCs is represented by the adventitial reticular cells present in the wall of the sinusoids of bone marrow tissue. Adventitial reticular cells form a layer on the abluminal side of ECs of the sinusoids, which is therefore not different from the relationship that PCs establish with ECs in capillaries and small vessels [39]. A number of studies have associated adventitial reticular cells with the stromal cells of bone marrow from which the so-called bone marrow MSCs/stromal stem cells are derived [40]. The ability of these cells to generate progenitors that can differentiate in cartilage, bone, and adipocytes closely resembles the properties of PCs.

Actually, both cell types express a set of common markers [41]. Adventitial reticular cells and the stromal cells of bone marrow have been shown to represent a specific cell population of skeletal stem cells devoted to bone growth and renewal as well as to participate in the establishment of the hematopoietic stem cell niche [39,42].

Over the years, a number of studies have indicated that, in addition to PCs and to adventitial reticular cells/stroma cells of bone marrow, a number of multipotent or lineage-restricted progenitor cell populations are present in the wall of postnatal vessels, where they are essentially mainly associated with the function of maintaining the structural integrity of the vascular system. Lineage-specific progenitors mainly dedicated to the replacement of ECs or to the generation of new smooth muscle cells have been identified in the arteries of adult tissues [19,43,44].

In addition to lineage-restricted progenitors, a number of studies have also identified multipotent stem/progenitor cells present in the wall of blood vessels. Most of these cell

populations are generically defined as MSCs, yet their characterization is still lagging behind given the inherited difficulties to distinguish MSCs from PCs [29,37,45–48]. Other studies have resulted in the initial characterization of additional multipotent cell populations of the vascular wall that bear some relationships with PCs: adventitial cells and myogenic ECs. Of note, these two cell populations share with PCs both the ability to differentiate into some mesodermal lineages and the expression of several MSC markers [28].

Adventitial cells, which are different from the “adventitial reticular cells” of bone marrow, were first isolated from the adipose stromal vascular fraction as CD34⁺ CD31⁻ CD45⁻ CD146⁻ expressing cells [49,50] with a lower efficiency to differentiate into adipocytes when compared with isogenic PCs [50]. Their localization in the adventitia can easily distinguish them from typical CD34⁺ ECs [47]. Intriguingly, adult adipose-derived adventitial cells appear to represent a source of MSCs clearly distinct from PCs [29].

Myogenic ECs have been identified in vessels from skeletal muscle where they can be identified by the expression of different myogenic markers, such as CD56 and PAX7, but also of endothelial markers, such as CD34, CD144, and von Willebrand factor (vWF) [51]. Myogenic ECs are currently defined as CD56⁺ CD34⁺ CD144⁺ CD45⁻ cells and are able to differentiate into skeletal muscle cells, chondrocytes, osteocytes, and adipocytes [52,53].

Altogether, adventitial cells and myogenic ECs have the capacity to proliferate and the potential to give rise to endothelial, smooth muscle, and additional mesenchymal cell types. Accordingly, the vascular wall appears to possess the characteristic of a niche-like environment, a concept of high relevance considering the involvement of the vascular compartment in physiological and pathological conditions [2,15,45,54,55].

PCs, MSCs, and the Perivascular Compartment

The term MSCs was introduced by Caplan to define cells derived from bone marrow that were able to differentiate in different mesenchymal lineages, including adipocytes, osteocytes, and chondrocytes [56]. After the original isolation from human bone marrow [57], MSCs have also been isolated from a wide variety of adult human organs and tissues by exploiting an isolation procedure based on the enzymatic digestion of the stromal vascular fraction of bioptic specimens [58–63].

In analogy to other adult stem cells, we still need to identify unique markers for recognizing MSCs, since all surface antigens routinely used to characterize MSCs are also expressed by a variety of unrelated cells (see Murray et al. [41] for a compelling list of MSCs and perivascular cells markers). Accordingly, MSCs are currently defined based on both operational and functional criteria: MSCs must be adherent to plastic, must possess self-renewing ability, and must be able to differentiate into at least adipogenic, osteogenic, and chondrogenic lineages, to express CD105, CD73, and CD90 while being negative for the expression of CD45, CD34, CD14 or CD11b, CD79 α , or CD19 and human leukocyte antigen (HLA)-DR surface molecules [64].

Despite extensive studies aimed to better define the *in vitro* properties of MSCs, once isolated from tissues, their localization and physiological role *in vivo* still remain to be clarified. Based on their nearly ubiquitous presence, it has been

proposed that *in vivo* MSCs might reside within the perivascular compartment of adult connective tissues [36,65,66].

Indeed, the identification of the multipotent properties of PCs supported the hypothesis that also MSCs might have a perivascular origin [30,65]. Studies of lineage tracing, based on neural-glial-2 (NG2), peroxisome proliferator-activated receptor gamma (PPAR γ), alkaline phosphatase (AP) and GLI1 expression, indicated that progenitors capable of differentiating *in vivo* into either osteogenic, adipogenic, or myogenic cells (ie, mesodermal progenitors) are localized in the perivascular niche of incisors, fat, and skeletal muscle, respectively [67–70]. However, the relationship between these progenitors from the perivascular niche and PCs is not yet completely determined.

Evidence supporting the association of *in vivo* multipotent MSCs with the perivascular compartment has been provided in bone marrow. Here, the adventitial reticular cells that surround bone marrow sinusoids are considered, along with bone marrow stromal cells, the endogenous progenitor of MSCs, given their ability to self-renew and to fully organize the complete hematopoietic environment of bone marrow [40,43]. Culture of adherent cells derived from adventitial reticular and stromal cells is referred to as bone marrow stromal cells or bone marrow MSCs.

Results from several laboratories have reported that MSCs isolated from different tissues displayed properties similar to bone marrow MSCs in terms of surface marker expression and growth rate. However, the multipotent and clonogenic abilities of MSCs from other tissues are less efficient with respect to those derived from bone marrow [71]. In this context, Peault's group reported that *in vivo* PCs, identified as such by the coexpression of known perivascular markers such as NG2, CD146, and PDGF-R β , when purified from various adult tissues and cultured *in vitro*, retain the expression of perivascular and mesenchymal markers and also express additional MSC markers, suggesting that the intimate connection between PCs and MSCs appears to be more than a hypothesis [37,46,72].

A comparison between MSCs from various sources, including bone marrow, and retinal cultured PCs initially indicated that also MSCs and PCs were similar in terms of immunophenotype and differentiation abilities, although they reported that CD146 was expressed only by PCs [73]. Other studies have shown that CD146 is expressed also by MSCs isolated from tissues other than bone marrow, although at variable levels with respect to PCs [74,75], as also discussed later. A more recent compelling comparison between bone marrow MSCs and PCs has revealed that MSCs and PCs share several immunophenotypic markers and are both able to differentiate toward adipogenic, osteogenic, and chondrogenic lineages, although their multipotent abilities were differentially dependent on the culture conditions [74].

Additional differences between MSCs and PCs were also observed in the analysis of the transcriptome of MSCs and PCs [74]. Evidence of differences between MSCs and PCs should not surprise, considering that MSCs are obtained without a prospective isolation and therefore represent a highly heterogeneous cell population containing progenitors with distinct differentiation abilities that vary depending on the tissue of origin [58,76–79]. Further differences between PCs and MSCs are also supported by the evidence that cultured PCs from skeletal muscle, but not MSCs from the same tissue, were able to fuse and form myotubes *in vitro*,

suggesting that PCs from skeletal muscle present a broader range of differentiation abilities than MSCs.

In line with this finding, a more recent comparison between isogenic MSCs and PCs from adipose tissue revealed that PCs are endowed with more efficient differentiation abilities than their MSCs counterparts, although both cell populations were nearly identical in terms of surface marker expression [75]. Opposite evidence in terms of differentiation abilities has been obtained in the myometrium, where PCs can only differentiate toward smooth muscle cells [80], whereas MSCs are able to differentiate toward adipogenic, osteogenic, and chondrogenic lineages [81]. Experiments with MSCs isolated from dental pulp and adipose tissue indicate that not all MSCs isolated from those tissues are derived from PCs [29,68].

Based on this evidence, we can conclude that, although the perivascular compartment contains mesodermal precursors such as PCs and MSCs, a direct relationship between PCs and MSCs, although possible, still remains to be formally proved in most tissues.

PCs: Surface Marker Expression and Procedures for Isolation and In Vitro Culture

PCs are currently isolated from human adult tissues using two different procedures: selection of perivascular cell populations by fluorescent-activated cell sorting (FACS) or selection of weakly adhering cells that emerge from culture of explants of biopsies enriched in small blood vessels. In some cases, these two approaches have been combined. Several markers associated with cells present in the perivascular compartment are currently known (see Murray et al. [41] for a compelling list of perivascular cells markers). Nevertheless, markers that can be univocally associated with PCs are still missing.

Studies performed on tissue biopsies have shown that PCs *in vivo* can be identified by three main markers. A widely used marker for characterization of PCs is the cell adhesion molecule CD146, which also recognizes adventitial reticular cells of the bone marrow [40] and is also present on cell surface of additional cell populations such as endothelial progenitors of the VSMC lineage [82], but also mature ECs [83]. A second marker is NG2, a proteoglycan also expressed by progenitors of oligodendrocytes and chondrocytes [84,85] and that is present on mural cells during vascular morphogenesis [86]. The last marker used for identification of PCs is the platelet-derived growth factor receptor beta (PDGFR β), the receptor for a powerful mitogen of cells of mesenchymal origin that also plays a pivotal role in vessel formation, being involved in differentiation and proliferation of both PCs and VSMCs [87,88].

In situ PCs also express α -smooth muscle actin and desmin, in addition to other mesodermal markers such as CD73, CD90, and CD105. Finally, *in vivo* PCs can be identified as they do not express endothelial and hematopoietic markers such as CD31, vWF, CD34, and CD45 [37,38]. PCs also express AP, although its expression has been formally observed *in vivo* only in skeletal muscle PCs [88]. Based on the combination of markers expressed by PCs *in vivo*, these cells have been purified from the stromal vascular fraction of adipose tissue as a population of cells positive for CD146 and negative for CD34, CD45, and CD31 by using multicolor

FACS. After expansion *in vitro*, purified PCs also express NG2, PDGFR β , and other mesodermal markers leading to the definition of a compelling PCs molecular signature based on the expression of CD146, NG2, PDGFR β , and AP and the absence of CD34, CD45, vWF, and CD144 [37]. Cell sorting based on these markers has also been exploited to isolate PCs from human fetal tissues, endometrium, heart, and also from skeletal muscle [37,89].

PCs from adult human skeletal muscle tissue are usually isolated following the technique of culture of explants starting from tissue biopsies. Nearly 2 weeks after the initial plating, small round-refractile cells start to emerge from the cultured explants. These cells are then harvested and expanded to obtain cultured PCs [38]. PCs derived by explant culture from skeletal muscle or from other adult tissues share the known surface marker profile identified *in vivo* and on FACS-purified cells [75,80,90]. A combination of the explant-culture protocol and FACS selection has been more recently introduced to isolate skeletal muscle PCs. This approach is based on the selection of AP-expressing cells from the population of weakly adhering cells emerging from skeletal muscle explant culture. Of note, this isolation procedure generates a population of cultured PCs again expressing the same molecular signature already reported [88,91].

PCs from Skeletal Muscle

The increased attention on the multipotent properties of PCs stems from the seminal work on embryonic mesoangioblasts [24,34]. The characterization of mouse embryo mesoangioblasts and later of postnatal adult PCs provided solid evidence that these cells, even when delivered systemically, are able to colonize skeletal muscle and to differentiate in healthy muscle fibers resulting in a significant functional recovery in dystrophic mice [92]. Mesoangioblasts, in fact, express a subset of integrins and receptors that efficiently allow migration through both the blood stream and vascular wall crossing [35,93].

In the following years, cell populations endowed of myogenic potential have also been isolated from canine's postnatal skeletal muscle biopsies. In analogy with previous results obtained in dystrophic mice, systemic delivery of healthy donor dog mesoangioblasts resulted in the improvement of muscle function in dystrophic dogs [94].

Finally, Cossu and coworkers used explant cultures of adult skeletal muscle biopsies to isolate human adult PCs [90]. Cultured PCs from human skeletal muscle, in line with mouse and dog adult cells, displayed a strong spontaneous myogenic potential *in vitro* and were also able to fuse with mouse muscle fibers once injected into the femoral artery of scid-mdx immunodeficient mice. In addition, cultured PCs differentiated *in vitro* also toward adipogenic and osteogenic lineages, thus combining biological properties of original mesoangioblasts [90].

The therapeutic potentials of PCs in contributing to skeletal muscle tissue regeneration when injected into pre-clinical models of muscular dystrophy reflect a physiological role of these cells. In fact, recent work by several groups has shown that in skeletal muscle tissue, PCs are part of a pool of cells that, in addition to the "proper" myogenic precursors (ie, satellite cells), can directly [88,95] or indirectly [96,97] contribute to the process of muscle repair and

regeneration. Indeed, lineage tracing of skeletal muscle PCs showed that these cells are able to enter the skeletal muscle niche compartment in the early stages of postnatal growth and to contribute to the formation of the adult satellite cell compartment. These PC-derived satellite cells can fuse into developing skeletal muscle fibers and contribute to normal muscle growth in unperturbed conditions during adult life and, even more, participate in regeneration of skeletal muscle tissue after injury [88]. Altogether, these data indicate that the observed ability of isolated and cultured PCs to enter the myogenic cell fate, when used for therapeutic protocols, reflects a tissue-specific commitment of these cells.

Based on the results obtained in murine and canine pre-clinical models of muscular dystrophy, a phase I/IIa clinical trial using cultured PCs was recently started. This trial aimed to treat pediatric patients affected by Duchenne muscular dystrophy with the intraarterial infusion of HLA-matched allogeneic PCs obtained from adult skeletal muscle of healthy donors. Unfortunately, the engraftment of the transplanted PCs was minimal and the overall efficacy of this treatment was negligible in terms of functional recovery, as compared with results obtained in preclinical models. Nevertheless, this study indicated that a cell therapy approach based on infusion to each patient of hundreds of millions PCs can be considered safe, providing an encouraging outcome for future improvements of the procedure [98].

PCs from Other Adult Human Tissues

The identification of multipotent PCs in skeletal muscle, the encouraging outcomes obtained in preclinical animal models, and the emerging role of PCs in tissue regeneration in physiological and pathological conditions inspired additional studies aimed at the isolation of PCs from other human adult tissues.

PCs have been isolated by FACS as CD146⁺ CD34⁻ CD56⁻ CD45⁻ cells from the stromal vascular fraction of adipose tissue from where a large number of PCs can be obtained [37,72]. Adipose tissue PC-derived cells are clonal cells able to give rise to adipocytes, osteocytes, and chondrocytes. When injected into skeletal muscle of cardiotoxin-treated mice, they are also able to contribute to fiber regeneration, although evidence for spontaneous skeletal muscle differentiation has not been provided. A more compelling analysis on adipogenic potential of distinct stromal cell populations revealed that PC-derived cells display a stronger tendency to differentiate into multilocular adipocytes than endothelial progenitors, supra adventitial cells, and mature ECs [50].

More recently, Lauvud et al. further confirmed that adipose PC-derived cells expressing CD146 are endowed with a more robust adipogenic potential than their CD146 negative counterpart [99]. Interestingly, FACS-sorted adipose PC-derived cells improved fracture healing when percutaneously injected into an atrophic nonunion rat model [100], giving promising results also for future clinical exploitation of the osteogenic potential of adipose PCs. In this context, the sorting procedure proposed by Crisan et al., which is considered the most accurate approach to isolate adipose PCs by FACS [46], has been slightly improved to obtain a clinically relevant number of cells without the need of expansion in culture.

PCs from adipose tissue have also been isolated as floating cells outgrowing from explant culture of fat tissue

biopsies, in strict analogy with the procedure used to isolate PCs from skeletal muscle. These cultured PCs express the classical pericytic markers, including CD146, AP, and NG2, whereas they do not express the endothelial markers CD31 and CD34. They are able to differentiate into adipocytes, osteocytes, and smooth muscle cells, whereas they are unable to spontaneously differentiate into skeletal muscle cells unless when cocultured with an established myogenic cell line [75]. As a matter of fact, PCs from adipose tissue either isolated through FACS selection or explant culture appear to possess comparable characteristics.

Interest in identifying cardiac stem cells also triggered studies on the isolation of human PCs from heart. Resident microvascular heart PCs were identified as cells surrounding microvessels and capillaries, which coexpressed CD146, NG2, and PDGFR β and were negative for endothelial markers. These cells were further isolated by FACS starting from the myocardium using a positive selection for CD146 and a negative selection for CD34, CD45, CD56, and CD117, in strict analogy with PCs from adipose tissue. Cultured heart PCs displayed null skeletal myogenic potential and limited cardiomyogenic capacity, being only committed to an immature cardiomyocytic phenotype. In contrast, heart PCs could be robustly differentiated toward adipogenic, osteogenic, and chondrogenic lineages [101].

Murine heart cell populations, endowed with strong cardiomyogenic ability, have been isolated by FACS as CD34 and NG2 positive cells or, after colony-forming assay, as colony-forming unit fibroblasts (CFU-Fs). Of note, CD34⁺ NG2⁺ cardiomyogenic cells failed to differentiate toward additional mesenchymal lineages, whereas cardiac CFU-Fs displayed adipogenic, osteogenic, and chondrogenic potentials [102,103]. These data indicate that, although homologous cell populations have not been isolated yet from human heart, distinct progenitors with different differentiation potentials can be found in the perivascular compartment of the heart. Intriguingly, heart cell populations that expressed pericytic markers appear to be selectively committed toward the cardiac phenotype.

A tissue characterized by the presence of a predominant smooth muscle tissue component is the uterus. The presence of PCs around microvessels in biopsies of endometrium has been revealed by immunostaining for CD146 and PDGFR β . Accordingly, these cells have been isolated by FACS, using CD146 and PDGFR β as selection markers, starting from the enzymatic digestion of endometrial biopsies. Endometrial PCs were capable of differentiating into multiple mesenchymal lineages, including smooth muscle. A comparative transcriptomic analysis between endometrial PCs, endometrial fibroblasts, and endometrial ECs revealed that freshly isolated PCs express genes involved in smooth muscle differentiation at higher levels with respect to the other cell populations [104].

PCs from uterus have been more recently isolated by explant culture of myometrial biopsies. These PCs from myometrium are similar to those isolated from the endometrium in terms of morphology and surface marker expression [80,104]. Nevertheless, myometrial PCs can readily differentiate only into smooth muscle cells, whereas they were totally incapable of differentiating into other mesenchymal lineages, including skeletal muscle differentiation. Both myometrial and endometrial PCs express notch receptors [80,105], whose activation is known to be involved in the

development of endometrium as well as in PCs differentiation [21,106,107]. However, inhibition of notch signaling had no effect on the properties of myometrial PCs, whereas it affected both gene expression and proliferation of PCs from the endometrium [80,108].

Based on the reported evidence, it appears that PCs from distinct tissues are endowed with different mesodermal potentials, although they are virtually indistinguishable in terms of morphology and marker expression. In addition, when considering adipose tissue, skeletal muscle, heart, and uterus, PCs appear to retain a preferential commitment toward the main cell type of the tissue where they reside. Intriguingly, this aspect has also been observed in bone marrow, where in situ adventitial reticular cells, which can be considered the bone marrow equivalent of PCs, showed a preferential tendency to differentiate into bone [40].

Very recently, Sacchetti et al. performed a compelling comparison between CD146⁺/CD34⁻/CD45⁻ cells isolated from different human tissues [109]. These authors reported that, in addition to marked differences between the cell populations analyzed in terms of transcriptomic signature, bone marrow-derived cells were skeletogenic but neither myogenic nor chondrogenic, whereas skeletal muscle-derived cells were myogenic, but not skeletogenic. Additional analysis of the differentiative properties of perinatal cord blood-derived cells indicated that these cells were chondro-osteogenic but not myogenic, further supporting the idea that perivascular/MSCs progenitors can be endowed with differentiation abilities closely related to the tissue of origin.

However, it should be noted that cell populations used by Bianco and collaborators were obtained using a prospective isolation protocol slightly different from that described by Peault's group [37,46]. In addition, previous studies based on different isolation strategies, culture conditions, and differentiation assays have provided results that differ from those reported by Sacchetti et al. [109–111]. Indeed, we should always be aware that even minimal changes in isolation and culture protocols might induce small variations in the cell populations obtained, which might then cause differences in the observed properties of the resulting cells. Nonetheless, even when using the same prospective isolation protocol, Sacchetti et al. [109] noted that only PCs from skeletal muscle were capable of spontaneously differentiating into skeletal muscle cells.

In this context, it is worth noting that induced pluripotent stem cells (iPSCs) obtained by reprogramming skeletal muscle PCs are endowed with better skeletal muscle differentiation efficiency than iPSCs obtained by fibroblasts reprogramming [112,113]. However, contrasting evidence on the ability of PCs and related cell populations from brain to spontaneously differentiate into neuronal lineages has been reported [114–117]. Altogether, currently available data on PCs isolated from adipose and cardiac tissues, endometrium, myometrium, bone marrow, and skeletal muscle appear to be more prone to differentiate toward the cell type specific of the tissue from where they were isolated.

Concluding Remarks

In this review, we attempted to describe the state of the art on PCs from adult human tissues with respect to their identification and their differentiation properties. Cells capable of differentiating into different lineages of mesodermal origin

have been isolated from several tissues of mice and humans. Among these cells, PCs have recently attracted the interest of several research teams because of their potential applications in cell therapy protocols and also for representing a potential source for MSCs. However, despite the high interest and of intensive investigation, we are still far from having attained a unique idea on the overall identity of PCs.

Despite the lack of specific surface markers that would allow to unambiguously label homogeneous populations of PCs, these cells can be identified in vivo as non-ECs (CD34⁻ and CD31⁻ cells) that natively express perivascular and mesenchymal markers (NG2, AP, PDGFR β , CD44, CD73, CD90, CD105, and CD146) [37,38,72,91]. However, these markers are not always all present on PCs from adult human tissues [41,72,118].

Prospective isolation of PCs can be obtained selecting for CD146⁺ CD34⁻CD45⁻CD56⁻ cells [37,46]. Once in culture, these cells retain the above-mentioned markers, but also express additional mesenchymal markers [37,67]. Nevertheless, these markers do not allow establishing a clear relationship between PCs and MSCs, and between PCs and the numerous progenitor cell populations found in the perivascular compartment or in the connective tissue of the different organs of the adult organism.

Initial results indeed claimed that PCs isolated from various tissues might share common traits, including growth properties, surface marker expression, and differentiation potencies. This initial enthusiasm has been tempered by more recent data obtained by different groups, which although contribute to expand our knowledge on biology of PCs, also have added additional information, suggesting that PCs may significantly differ from MSCs [29,68]. Furthermore, evidence has been provided indicating additional variability among populations of PCs. In this context, recent data suggest that even within the same tissue, PCs may differ on the basis of specific properties that include the type and size of blood vessels of residence and the interactions that they establish with other cells [28,72,118]. In addition, PCs within a given tissue may functionally behave differently under pathological conditions [119–121].

In conclusion, work from several laboratories during the past few years has provided a large body of information on the properties of PCs. Noteworthy, converging evidence derived from studies mainly performed on PCs isolated from skeletal muscle, bone marrow, and adipose tissue and new results obtained from additional tissues including endometrium, myometrium, and cardiac tissue suggest that PCs isolated from different tissues, even if they might present a varied range of differentiation properties, appear to have a characteristic preference to differentiate toward the specific cell type of the tissue from where they have been isolated. This is likely due to the local cues imposed by the environment where PCs reside, which might reflect the cell renewal and repair processes required for maintenance of the "tissue homeostasis" of each specific tissue.

Acknowledgments

This work was supported by a PAR FAS 2007–2013 grant, ToRSADE, from Regione Toscana to Vincenzo Sorrentino, and a MIUR-FIR 2013 RBFR13A20K grant to Enrico Pierantozzi.

Author Disclosure Statement

The authors declare no competing financial interests.

References

1. Zimmermann KW. (1923). Der feinere bau der blutcapillares. *Z Anat Entwicklungsgesch* 68:3–109.
2. Armulik A, G Genové and C Betsholtz. (2011). Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. *Dev Cell* 21:193–215.
3. Díaz-Flores L, R Gutiérrez, JF Madrid, H Varela, F Valladares, E Acosta, P Martín-Vasallo and J Díaz-Flores. (2009). Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. *Histol Histopathol* 24:909–969.
4. Caruso RA, F Fedele, G Finocchiaro, G Pizzi, M Nunnari, G Gitto, V Fabiano, A Parisi and A Venuti. (2009). Ultrastructural descriptions of pericyte/endothelium peg-socket interdigitations in the microvasculature of human gastric carcinomas. *Anticancer Res* 29:449–453.
5. Larson DM, MP Carson and CC Haudenschild. (1987). Junctional transfer of small molecules in cultured bovine brain microvascular endothelial cells and pericytes. *Microvasc Res* 34:184–199.
6. Gerhardt H, H Wolburg and C Redies. (2000). N-cadherin mediates pericytic-endothelial interaction during brain angiogenesis in the chicken. *Dev Dyn* 218:472–479.
7. Cuevas P, JA Gutierrez-Diaz, D Reimers, M Dujovny, FG Diaz and JI Ausman. (1984). Pericyte endothelial gap junctions in human cerebral capillaries. *Anat Embryol* 170:155–159.
8. Tilton RG, C Kilo and JR Williamson. (1979). Pericyte-endothelial relationships in cardiac and skeletal muscle capillaries. *Microvasc Res* 18:325–335.
9. Rhodin JA. (1968). Ultrastructure of mammalian venous capillaries, venules, and small collecting veins. *J Ultrastruct Res* 25:452–500.
10. Vegge T. (1972). A study of the ultrastructure of the small iris vessels in the vervet monkey (*Ceropithecus aethiops*). *Z Zellforsch Mikrosk Anat* 123:195–208.
11. Gerhardt H and C Betsholtz. (2003). Endothelial-pericyte interactions in angiogenesis. *Cell Tissue Res* 314:15–23.
12. Von Tell D, A Armulik and C Betsholtz. (2006). Pericytes and vascular stability. *Exp Cell Res* 312:623–629.
13. Diaz-Flores L, R Gutierrez, H Varela, N Rancel and F Valladares. (1991). Microvascular pericytes: a review of their morphological and functional characteristics. *Histol Histopathol* 6:269–286.
14. Sims DE. (1986). The pericyte—a review. *Tissue Cell* 18:153–174.
15. Hall A. (2006). Review of the pericyte during angiogenesis and its role in cancer and diabetic retinopathy. *Toxicol Pathol* 34:763–775.
16. Van Dijk CGM, FE Nieuweboer, JY Pei, YJ Xu, P Burgisser, E Van Mulligen, HEI Pzzouzi, DJ Duncker, MC Verhaar and C Cheng. (2015). The complex mural cell: pericyte function in health and disease. *Int J Cardiol* 190:75–89.
17. Steinbach SK and M Husain. (2016). Vascular smooth muscle cell differentiation from human stem/progenitor cells. *Methods* 101:85–92.
18. Mandarino LJ, N Sundarraj, J Finlayson and JR Hassell. (1993). Regulation of fibronectin and laminin synthesis by retinal capillary endothelial cells and pericytes in vitro. *Exp Eye Res* 57:609–621.
19. Psaltis PJ and RD Simari. (2015). Vascular wall progenitor cells in health and disease. *Circ Res* 116:1392–1412.
20. Edelman DA, Y Jiang, J Tyburski, RF Wilson and C Steffes. (2006). Pericytes and their role in microvasculature homeostasis. *J Surg Res* 135:305–311.
21. Cappellari O and G Cossu. (2013). Pericytes in development and pathology of skeletal muscle. *Circ Res* 113:341–347.
22. Geevarghese A and IM Herman. (2014). Pericyte-endothelial crosstalk: implications and opportunities for advanced cellular therapies. *Transl Res* 163:296–306.
23. Sweeney MD, S Ayyadurai and BV Zlokovic. (2016). Pericytes of the neurovascular unit: key functions and signaling pathways. *Nat Neurosci* 19:771–783.
24. De Angelis L, L Berghella, M Coletta, L Lattanzi, M Zanchi, MG Cusella-De Angelis, C Ponzetto and G Cossu. (1999). Skeletal myogenic progenitors originating from embryonic dorsal aorta coexpress endothelial and myogenic markers and contribute to postnatal muscle growth and regeneration. *J Cell Biol* 147:869–877.
25. Crisan M, M Corselli, WCW Chen and B Péault. (2012). Perivascular cells for regenerative medicine. *J Cell Mol Med* 16:2851–2860.
26. Gokcinar-Yagci B, O Ozyuncu and B Celebi-Saltik. (2016). Isolation, characterisation and comparative analysis of human umbilical cord vein perivascular cells and cord blood mesenchymal stem cells. *Cell Tissue Bank* 17:345–352.
27. Tilki D, HP Hohn, B Ergun, S Rafii and S Ergun. (2009). Emerging biology of vascular wall progenitor cells in health and disease. *Trends Mol Med* 15:501–509.
28. Chen WCW, B Péault and J Huard. (2015). Regenerative translation of human blood-vessel-derived MSC precursors. *Stem Cells Int*; DOI: 10.1155/2015/375187.
29. Corselli M, CW Chen, B Sun, S Yap, JP Rubin and B Peault. (2012). The tunica adventitia of human arteries and veins as a source of mesenchymal stem cells. *Stem Cells Dev* 21:1299–1308.
30. Caplan AI. (2008). All MSCs are pericytes?. *Cell Stem Cell* 3:229–230.
31. Majesky MW. (2007). Developmental basis of vascular smooth muscle diversity. *Arterioscler Thromb Vasc Biol* 27:1248–1258.
32. Sinha S, D Iyer and A Granata. (2014). Embryonic origins of human vascular smooth muscle cells: implications for in vitro modeling and clinical application. *Cell Mol Life Sci* 71:2271–2288.
33. Azzoni E, V Conti, L Campana, A Dellavalle, RH Adams, G Cossu and S Brunelli. (2014). Hemogenic endothelium generates mesoangioblasts that contribute to several mesodermal lineages in vivo. *Development* 141:1821–1834.
34. Minasi MG, M Riminucci, L De Angelis, U Borello, B Berarducci, A Innocenzi, A Caprioli, D Sirabella, M Baiocchi, et al. (2002). The meso-angioblast: a multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. *Development* 129:2773–2783.
35. Tagliafico E, S Brunelli, A Bergamaschi, L De Angelis, R Scardigli, D Galli, R Battini, P Bianco, S Ferrari, G Cossu and S Ferrari. (2004). TGF/BMP activate the smooth muscle/bone differentiation programs in mesoangioblasts. *J Cell Sci* 117:4377–4388.
36. Bianco P and G Cossu. (1999). Uno, nessuno e centomila: searching for the identity of mesodermal progenitors. *Exp Cell Res* 251:257–263.

37. Crisan M, S Yap, L Casteilla, C-W Chen, M Corselli, TS Park, G Andriolo, B Sun, B Zheng, et al. (2008). A perivascular origin for mesenchymal stem cells in multiple human organs. *Cell Stem Cell* 3:301–313.
38. Tonlorenzi R, A Dellavalle, E Schnapp, G Cossu and M Sampaolesi. (2007). Isolation and characterization of mesangioblast from mouse, dog and human tissues. *Curr Protoc Stem Cell Biol Chapter 2:Unit 2B.1*.
39. Bianco P. (2014). “Mesenchymal” stem cells. *Annu Rev Cell Dev Biol* 30:677–704.
40. Sacchetti B, A Funari, S Michienzi, S Di Cesare, S Pieranti, I Saggio, E Tagliafico, S Ferrari, PG Robey, M Riminucci and P Bianco. (2007). Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. *Cell* 131:324–336.
41. Murray IR, CC West, WR Hardy, AW James, TS Park, A Nguyen, T Tawonsawatruk, L Lazzari, C Soo and B Péault. (2014). Natural history of mesenchymal stem cells, from vessel walls to culture vessels. *Cell Mol Life Sci* 71:1353–1374.
42. Kassem M and P Bianco. (2015). Skeletal stem cells in space and time. *Cell* 160:17–19.
43. Ingram DA, LE Mead, DB Moore, W Woodard, A Fenoglio and MC Yoder. (2005). Vessel wall-derived endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial progenitor cells. *Blood* 105:2783–2786.
44. Bearzi C, A Leri, F Lo Monaco, M Rota, A Gonzalez, T Hosoda, M Pepe, K Qanud, C Ojaimi, et al. (2009). Identification of a coronary vascular progenitor cell in the human heart. *Proc Natl Acad Sci U S A* 106:15885–15890.
45. Murray IR and B Péault. (2015). Q&A: mesenchymal stem cells—where do they come from and is it important? *BMC Biol* 13:99.
46. Corselli M, M Crisan, IR Murray, CC West, J Scholes, F Codrea, N Khan and B Péault. (2013). Identification of perivascular mesenchymal stromal/stem cells by flow cytometry. *Cytometry A* 83:714–720.
47. Campagnolo P, D Cesselli, A Al Haj Zen, AP Beltrami, N Krankel, R Katare, G Angelini, C Emanuelli and P Madeddu. (2010). Human adult vena saphena contains perivascular progenitor cells endowed with clonogenic and proangiogenic potential. *Circulation* 121:1735–1745.
48. Park TS, M Gavina, C-W Chen, B Sun, P-N Teng, J Huard, BM Deasy, L Zimmerlin and B Péault. (2011). Placental perivascular cells for human muscle regeneration. *Stem Cells Dev* 20:451–463.
49. Lin G, M Garcia, H Ning, L Banie, Y-L Guo, TF Lue and C-S Lin. (2008). Defining stem and progenitor cells within adipose tissue. *Stem Cells Dev* 17:1053–1063.
50. Zimmerlin L, VS Donnenberg, ME Pfeifer, EM Meyer, B Péault, P Rubin and AD Donnenberg. (2010). Stromal vascular progenitors in adult human adipose tissue. *Cytometry A* 77:22–30.
51. Tamaki T, A Akatsuka, K Ando, Y Nakamura, H Matsuzawa, T Hotta, RR Roy and VR Edgerton. (2002). Identification of myogenic-endothelial progenitor cells in the interstitial spaces of skeletal muscle. *J Cell Biol* 157:571–577.
52. Zheng B, B Cao, M Crisan, B Sun, G Li, A Logar, S Yap, JB Pollett, L Drowley, et al. (2007). Prospective identification of myogenic endothelial cells in human skeletal muscle. *Nat Biotechnol* 25:1025–1034.
53. Zheng B, G Li, WCW Chen, BM Deasy, JB Pollett, B Sun, L Drowley, B Gharaibeh, A Usas, B Péault and J Huard. (2013). Human myogenic endothelial cells exhibit chondrogenic and osteogenic potentials at the clonal level. *J Orthop Res* 31:1089–1095.
54. Bodnar RJ, L Satish, CC Yates and A Wells. (2016). Pericytes: a newly recognized player in wound healing. *Wound Repair Regen* 24:204–214.
55. Mills SJ, AJ Cowin and P Kaur. (2013). Pericytes, mesenchymal stem cells and the wound healing process. *Cells* 2:621–634.
56. Caplan A. (1991). Mesenchymal stem cells. *J Orthop Res* 9:641–650.
57. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig and DR Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. *Science* 284:143–147.
58. Zuk PA, M Zhu, H Mizuno, J Huang, JW Futrell, AJ Katz, P Benhaim, HP Lorenz and MH Hedrick. (2001). Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng* 7:211–228.
59. Toma JG, M Akhavan, KJL Fernandes, F Barnabé-Heider, A Sadikot, DR Kaplan and FD Miller. (2001). Isolation of multipotent adult stem cells from the dermis of mammalian skin. *Nat Cell Biol* 3:778–784.
60. In’t Anker PS, SA Scherjon, C Kleijburg-van der Keur, GMJS de Groot-Swings, FHJ Claas, WE Fibbe and HHH Kanhai. (2004). Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. *Stem Cells* 22:1338–1345.
61. Beltrami AP, D Cesselli, N Bergamin, P Marcon, S Rigo, E Puppato, F D’Aurizio, R Verardo, S Piazza, et al. (2007). Multipotent cells can be generated in vitro from several adult human organs (heart, liver, and bone marrow). *Blood* 110:3438–3446.
62. Gallo R, F Gambelli, B Gava, F Sasdelli, V Tellone, M Masini, P Marchetti, F Dotta and V Sorrentino. (2007). Generation and expansion of multipotent mesenchymal progenitor cells from cultured human pancreatic islets. *Cell Death Differ* 14:1860–1871.
63. da Silva Meirelles L, PC Chagastelles and NB Nardi. (2006). Mesenchymal stem cells reside in virtually all post-natal organs and tissues. *J Cell Sci* 119:2204–2213.
64. Dominici M, K Le Blanc, I Mueller, I Slaper-Cortenbach, F Marini, D Krause, R Deans, A Keating, D Prockop and E Horwitz. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 8:315–317.
65. Cossu G and P Bianco. (2003). Mesoangioblasts—vascular progenitors for extravascular mesodermal tissues. *Curr Opin Genet Dev* 13:537–542.
66. Kfoury Y and DT Scadden. (2015). Mesenchymal cell contributions to the stem cell niche. *Cell Stem Cell* 16:239–253.
67. Tang W, D Zeve, JM Suh, D Bosnakovski, M Kyba, RE Hammer, MD Tallquist and JM Graff. (2008). White fat progenitors reside in the adipose vasculature. *Science* 322:583–586.
68. Feng J, A Mantesso, C De Bari, A Nishiyama and PT Sharpe. (2011). Dual origin of mesenchymal stem cells contributing to organ growth and repair. *Proc Natl Acad Sci U S A* 108:6503–6508.
69. Dellavalle A, G Maroli, D Covarello, E Azzoni, A Innocenzi, L Perani, S Antonini, R Sambasivan, S Brunelli, S Tajbakhsh and G Cossu. (2011). Pericytes resident in

- postnatal skeletal muscle differentiate into muscle fibres and generate satellite cells. *Nat Commun* 2:411–499.
70. Zhao H, J Feng, K Seidel, S Shi, O Klein, P Sharpe and Y Chai. (2014). Secretion of shh by a neurovascular bundle niche supports mesenchymal stem cell homeostasis in the adult mouse incisor. *Cell Stem Cell* 14:160–173.
 71. Wagner W, F Wein, A Seckinger, M Frankhauser, U Wirkner, U Krause, J Blake, C Schwager, V Eckstein, W Ansoerge and AD Ho. (2005). Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. *Exp Hematol* 33:1402–1416.
 72. Crisan M, C-W Chen, M Corselli, G Andriolo, L Lazzari and B Péault. (2009). Perivascular multipotent progenitor cells in human organs. *Ann N Y Acad Sci* 1176:118–123.
 73. Covas DT, RA Panepucci, AM Fontes, WA Silva, MD Orellana, MCC Freitas, L Neder, ARD Santos, LC Peres, MC Jamur and MA Zago. (2008). Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. *Exp Hematol* 36:642–654.
 74. Roobrouck VD, C Clavel, SA Jacobs, F Ulloa-Montoya, S Crippa, A Sohni, SJ Roberts, FPLuyten, SW Van Gool, et al. (2011). Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditions. *Stem Cells* 29:871–882.
 75. Pierantozzi E, M Badin, B Vezzani, C Curina, D Randazzo, F Petraglia, D Rossi and V Sorrentino. (2015). Human pericytes isolated from adipose tissue have better differentiation abilities than their mesenchymal stem cell counterparts. *Cell Tissue Res* 361:769–778.
 76. Muraglia A, R Cancedda and R Quarto. (2000). Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. *J Cell Sci* 113:1161–1166.
 77. Chen FG, WJ Zhang, D Bi, W Liu, X Wei, FF Chen, L Zhu, L Cui and Y Cao. (2007). Clonal analysis of nestin⁻vimentin⁺ multipotent fibroblasts isolated from human dermis. *J Cell Sci* 120 (Pt 16):2875–2883.
 78. Manini I, L Gulino, B Gava, E Pierantozzi, C Curina, D Rossi, A Brafa, C D’Aniello and V Sorrentino. (2011). Multi-potent progenitors in freshly isolated and cultured human mesenchymal stem cells: a comparison between adipose and dermal tissue. *Cell Tissue Res* 344:85–95.
 79. Pierantozzi E, B Gava, I Manini, F Roviello, G Marotta, M Chiavarelli and V Sorrentino. (2011). Pluripotency regulators in human mesenchymal stem cells: expression of NANOG but not of OCT-4 and SOX-2. *Stem Cells Dev* 20:915–923.
 80. Pierantozzi E, B Vezzani, M Badin, C Curina, FM Severi, F Petraglia, D Randazzo, D Rossi and V Sorrentino. (2016). Tissue-specific cultured human pericytes: perivascular cells from smooth muscle tissue have restricted mesodermal differentiation ability. *Stem Cells Dev* 25:674–686.
 81. Ono M, T Maruyama, H Masuda, T Kajitani, T Nagashima, T Arase, M Ito, K Ohta, H Uchida, et al. (2007). Side population in human uterine myometrium displays phenotypic and functional characteristics of myometrial stem cells. *Proc Natl Acad Sci U S A* 104:18700–18705.
 82. Espagnolle N, F Guilloton, F Deschaseaux, M Gadelorge, L Sensébé and P Bourin. (2014). CD146 expression on mesenchymal stem cells is associated with their vascular smooth muscle commitment. *J Cell Mol Med* 18:104–114.
 83. Bardin N, F Anfosso, JM Massé, E Cramer, F Sabatier, A Le Bivic, J Sampol and F Dignat-George. (2001). Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion. *Blood* 98:3677–3684.
 84. Fukushi JI, M Inatani, Y Yamaguchi and WB Stallcup. (2003). Expression of NG2 proteoglycan during endochondral and intramembranous ossification. *Dev Dyn* 228:143–148.
 85. Nishiyama A, M Komitova, R Suzuki and X Zhu. (2009). Polydendrocytes (NG2 cells): multifunctional cells with lineage plasticity. *Nat Rev Neurosci* 10:9–22.
 86. Ozerdem U, KA Grako, K Dahlin-Huppe, E Monosov and WB Stallcup. (2001). NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. *Dev Dyn* 222:218–227.
 87. Magnusson PU, C Looman, A Ahgren, Y Wu, L Claesson-Welsh and RL Heuchel. (2007). Platelet-derived growth factor receptor- β constitutive activity promotes angiogenesis in vivo and in vitro. *Arterioscler Thromb Vasc Biol* 27:2142–2149.
 88. Hellstrom M, M Kalen, P Lindhal, A Abramsson and C Betsholtz. (1999). Role of PDGF-B and PDGFR- β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in mice. *Development* 126:3047–3055.
 89. Chen WCW, JE Baily, M Corselli, ME Díaz, B Sun, G Xiang, GA Gray, J Huard and B Péault. (2015). Human myocardial pericytes: multipotent mesodermal precursors exhibiting cardiac specificity. *Stem Cells* 33:557–573.
 90. Dellavalle A, M Sampaolesi, R Tonlorenzi, E Tagliafico, B Sacchetti, L Perani, A Innocenzi, BG Galvez, G Messina, et al. (2007). Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. *Nat Cell Biol* 9:255–267.
 91. Quattrocchi M, G Palazzolo, I Perini, S Crippa, M Casano and M Sampaolesi. (2012). Mouse and human mesoangioblasts: isolation and characterization from adult skeletal muscles. *Myogenes Methods Protoc* 798:65–76.
 92. Sampaolesi M, Y Torrente, A Innocenzi, R Tonlorenzi, G D’Antona, MA Pellegrino, R Barresi, N Bresolin, MG De Angelis, et al. (2003). Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. *Science* 301:487–492.
 93. Aguilera KY and RA Brekken. (2014). Recruitment and retention: factors that affect pericyte migration. *Cell Mol Life Sci* 71:299–309.
 94. Sampaolesi M, S Blot, G D’Antona, N Granger, R Tonlorenzi, A Innocenzi, P Mognol, J-L Thibaud, BG Galvez, et al. (2006). Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. *Nature* 444:574–579.
 95. Tedesco FS, A Dellavalle, J Diaz-manera, G Messina and G Cossu. (2010). Review series repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. *J Clin Invest* 120:11–19.
 96. Pannérec A, L Formicola, V Besson, G Marazzi and DA Sassoon. (2013). Defining skeletal muscle resident progenitors and their cell fate potential. *Stem Cell Regen* 140:2879–2891.
 97. Pannérec A, G Marazzi and D Sassoon. (2012). Stem cells in the hood: the skeletal muscle niche. *Trends Mol Med* 18:599–606.

98. Cossu G, SC Previtali, S Napolitano, MP Cicalese, FS Tedesco, F Nicastro, M Noviello, U Roostalu, MG Natali Sora, et al. (2015). Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy. *EMBO Mol Med* 7:1513–1528.
99. Lauvruud AT, P Kelk, M Wiberg and PJ Kingham. (2016). Characterization of human adipose tissue-derived stem cells with enhanced angiogenic and adipogenic properties. *J Tissue Eng Regen Med* [Epub ahead of print]; DOI: 10.1002/term.2147.
100. Tawonsawatruk T, CC West, IR Murray, C Soo, B Péault and AHRW Simpson. (2016). Adipose derived pericytes rescue fractures from a failure of healing-non-union. *Sci Rep* 6:22779.
101. Chen W, J Baily, M Corselli, M Díaz, B Sun, G Xiang, G Gray, J Huard and B Péault. (2015). Human myocardial pericytes: multipotent mesodermal precursors exhibiting cardiac specificity. *Stem Cells* 33:557–573.
102. Galvez BG, M Sampaolesi, A Barbuti, A Crespi, D Covarello, S Brunelli, A Dellavalle, S Crippa, G Balconi, et al. (2008). Cardiac mesoangioblasts are committed, self-renewable progenitors, associated with small vessels of juvenile mouse ventricle. *Cell Death Differ* 15:1417–1428.
103. Chong JJH, V Chandrakanthan, M Xaymardan, NS Asli, J Li, I Ahmed, C Heffernan, MK Menon, CJ Scarlett, et al. (2011). Adult cardiac-resident MSC-like stem cells with a proepicardial origin. *Cell Stem Cell* 9:527–540.
104. Schwab KE and CE Gargett. (2007). Co-expression of two perivascular cell markers isolates mesenchymal stem-like cells from human endometrium. *Hum Reprod* 22:2903–2911.
105. Spitzer TLB, A Rojas, Z Zelenko, L Aghajanova, DW Erikson, F Barragan, M Meyer, JS Tamaresis, AE Hamilton, JC Irwin and LC Giudice. (2012). Perivascular human endometrial mesenchymal stem cells express pathways relevant to self-renewal, lineage specification, and functional phenotype. *Biol Reprod* 86:58.
106. Quattrocchi M, D Costamagna, G Giacomazzi, J Camps and M Sampaolesi. (2014). Notch signaling regulates myogenic regenerative capacity of murine and human mesoangioblasts. *Cell Death Dis* 5:e1448.
107. Mikhailik A, J Mazella, S Liang and L Tseng. (2009). Notch ligand-dependent gene expression in human endometrial stromal cells. *Biochem Biophys Res Commun* 388:479–482.
108. Murakami K, YH Lee, ES Lucas, YW Chan, RP Durairaj, S Takeda, JD Moore, BK Tan, S Quenby, et al. (2014). Decidualization induces a secretome switch in perivascular niche cells of the human endometrium. *Endocrinology* 155:4542–4553.
109. Sacchetti B, A Funari, C Remoli, G Giannicola, G Kogler, S Liedtke, G Cossu, M Serafini, M Sampaolesi, et al. (2016). No identical “Mesenchymal Stem Cells” at different times and sites: human committed progenitors of distinct origin and differentiation potential are incorporated as adventitial cells in microvessels. *Stem Cell Reports* 6:897–913.
110. Lojewski X, S Srimasorn, J Rauh, S Francke, M Wobus, V Taylor, MJ Arauzo-Bravo, S Hallmeyer-Elgner, M Kirsch, et al. (2015). Perivascular mesenchymal stem cells from the adult human brain harbor no intrinsic neuroectodermal but high mesodermal differentiation potential. *Stem Cells Transl Med* 4:1223–1233.
111. Miranda HC, RH Herai, C Hassibe Thomé, GG Gomes, RA Panepucci, M Delgado, ODT Covas, AR Muotri, LJ Greene and VM Faca. (2012). A quantitative proteomic and transcriptomic comparison of human mesenchymal stem cells from bone marrow and umbilical cord vein. *Proteomics* 12:2607–2617.
112. Quattrocchi M, G Palazzolo, G Floris, P Schöffski, L Anastasia, A Orlacchio, T Vandendriessche, MKL Chuah, G Cossu, C Verfaillie and M Sampaolesi. (2011). Intrinsic cell memory reinforces myogenic commitment of pericyte-derived iPSCs. *J Pathol* 223:593–603.
113. Dar A, H Domev, O Ben-Yosef, M Tzukerman, N Zeevi-Levin, A Novak, I Germanguz, M Amit and J Itskovitz-Eldor. (2012). Multipotent vasculogenic pericytes from human pluripotent stem cells promote recovery of murine ischemic limb. *Circulation* 125:87–89.
114. Karow M, R Sánchez, C Schichor, G Masserdotti, F Ortega, C Heinrich, S Gascón, MA Khan, DC Lie, et al. (2012). Reprogramming of pericyte-derived cells of the adult human brain into induced neuronal cells. *Cell Stem Cell* 11:471–476.
115. Paul G, I Ozen, NS Christophersen, T Reinbothe, J Bengzon, E Visse, K Jansson, K Dannaes, C Henriques-Oliveira, et al. (2012). The adult human brain harbors multipotent perivascular mesenchymal stem cells. *PLoS One* 7:e35577.
116. Park TI, H Monzo, EW Mee, PS Bergin, HH Teoh, JM Montgomery, RLM Faull, MA Curtis and M Dragunow. (2012). Adult human brain neural progenitor cells (NPCs) and fibroblast-like cells have similar properties in vitro but only NPCs differentiate into neurons. *PLoS One* 7:e37742.
117. Ozen I, J Boix and G Paul. (2012). Perivascular mesenchymal stem cells in the adult human brain: a future target for neuroregeneration? *Clin Transl Med* 1:30.
118. Murfee WL, TC Skalak and SM Peirce. (2005). Differential arterial/venous expression of NG2 proteoglycan in perivascular cells along microvessels: identifying a venule-specific phenotype. *Microcirculation* 12:151–160.
119. Birbrair A, T Zhang, ZM Wang, ML Messi, GN Enikolopov, A Mintz and O Delbono. (2013). Role of pericytes in skeletal muscle regeneration and fat accumulation. *Stem Cells Dev* 22:2298–2314.
120. Birbrair A, T Zhang, ZM Wang, ML Messi, GN Enikolopov, A Mintz and O Delbono. (2013). Skeletal muscle pericyte subtypes differ in their differentiation potential. *Stem Cell Res* 10:67–84.
121. Birbrair A, T Zhang, DC Files, S Mannava, T Smith, ZM Wang, ML Messi, A Mintz and O Delbono. (2014). Type-1 pericytes accumulate after tissue injury and produce collagen in an organ-dependent manner. *Stem Cell Res Ther* 5:122.

Address correspondence to:

Vincenzo Sorrentino, MD

Molecular Medicine Section

Department of Molecular and Developmental Medicine

University of Siena

Via Aldo Moro 2

Siena 53100

Italy

E-mail: vincenzo.sorrentino@unisi.it

Received for publication June 19, 2016

Accepted after revision August 22, 2016

Republished on Liebert Instant Online August 22, 2016